moxifloxacin has been researched along with gatifloxacin in 299 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (gatifloxacin) | Trials (gatifloxacin) | Recent Studies (post-2010) (gatifloxacin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,047 | 131 | 268 |
| Protein | Taxonomy | moxifloxacin (IC50) | gatifloxacin (IC50) |
|---|---|---|---|
| DNA gyrase subunit A | Escherichia coli K-12 | 0.5 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.5 | |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | 1.2 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 9.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.67) | 18.2507 |
| 2000's | 192 (64.21) | 29.6817 |
| 2010's | 92 (30.77) | 24.3611 |
| 2020's | 13 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Keserü, GM | 1 |
| Anquetin, G; Derouin, F; Farhati, K; Gozalbes, R; Greiner, J; Guedj, R; Mahmoudi, N; Rouquayrol, M; Santillana-Hayat, M; Vierling, P | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Bradbury, BJ; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Ou, Y; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Klugman, KP; Levin, BR; McGee, L; Rozen, DE | 1 |
| Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Courvalin, P; Galimand, M; Périchon, B | 1 |
| Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S | 1 |
| Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA | 1 |
| Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
| Daw-Garza, A; Lozano-Garza, HG; Ocampo-Candiani, J; Rocha, NC; Said-Fernández, S; Vera-Cabrera, L; Waksman de Torres, N; Welsh, O | 1 |
| Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N | 1 |
| Arhin, FF; Caron, L; Delorme, D; Dietrich, E; Fadhil, I; Ferreira, SS; Houghton, TJ; Kang, T; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Rafai Far, A; Sarmiento, I; Tanaka, KS; Viens, F | 1 |
| Arhin, FF; Delorme, D; Dietrich, E; Fadhil, I; Far, AR; Ferreira, SS; Houghton, TJ; Kang, T; Lafontaine, Y; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Sarmiento, I; Tanaka, KS; Viens, F | 1 |
| Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Kisanga, ER; van den Boogaard, J | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Barbanti, F; Barbut, F; Louie, T; Mastrantonio, P; Spigaglia, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| da Silva, PA; Hoffner, S; Jureen, P; Martin, A; Palomino, JC; Portaels, F; Vandamme, P; Von Groll, A | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Anquetin, G; Biot, C; Dive, D; Dubar, F; Khalife, J; Pradines, B | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Disratthakit, A; Doi, N | 1 |
| Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
| Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA | 1 |
| Drlica, K; German, N; Kerns, RJ; Malik, M; Marks, KR; Schwanz, HA | 1 |
| Sen, S; Sinha, N | 1 |
| Chai, Y; Guo, HY; Li, SJ; Liu, ML; Wang, B; Wang, JX; Zhang, YB | 1 |
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Anquetin, G; Aubry, A; Capton, E; Gomez, C; Jarlier, V; Lamouri, A; Pantel, A; Ponien, P; Serradji, N | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Guo, M; Li, YJ; Liu, Y; Piao, HR; Song, MX; Sun, LP; Wu, Y; Zheng, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Hou, SP; Li, YR; Liu, JC; Ma, LX; Piao, HR; Wang, MX; Zheng, CJ | 1 |
| Gou, C; Li, C; Li, XZ; Li, YR; Liu, HY; Liu, JC; Piao, HR; Zhang, ML; Zheng, CJ | 1 |
| Guo, M; Li, C; Li, YR; Liu, JC; Piao, HR; Sun, LP; Zhang, TY; Zheng, CJ | 1 |
| Lynch, AS; Ma, Z | 1 |
| Chi, KQ; Liu, HY; Piao, HR; Sun, LP; Wei, ZY; Yu, ZK; Zheng, CJ | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Jin, XJ; Li, MY; Piao, HR; Sun, LP; Yu, ZK; Zhang, TY; Zheng, CJ | 1 |
| Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ | 1 |
| Cheng, H; Deng, X; Fu, Z; Liang, Z; Song, M; Wang, S; Wang, Z; Zhou, S | 1 |
| Piao, HR; Sun, LP; Wu, J; Zhang, TY; Zheng, CJ | 1 |
| Du, H; Li, J; Liu, H; Piao, H; Sun, D; Sun, L; Zheng, C | 1 |
| Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K | 1 |
| Chen, L; Chen, Z; Fan, Y; Gao, F; Lu, G; Ma, L | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Agrawal, R; Barathi, VA; Beuerman, RW; Chan, LW; Jie, TY; Koh, SK; Lakshminarayanan, R; Leng, ET; Mayandi, V; Sebastian, TM; Somaraju Chalasani, ML; Ting, DSJ; Urf Turabe Fazil, MH; Varadarajan, J; Verma, NK; Xi, Q; Zhou, L | 1 |
| Dana, S; Dhar, SK; Gurung, SK; Kumar, S; Mondal, N; Mukhopadhyay, P; Valissery, P | 1 |
| Brady, SF; Koirala, B; Peek, J | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Bauernfeind, A | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W | 1 |
| Anderson, ME; Mazur, A; Roden, DM; Yang, T | 1 |
| Gleckman, R | 1 |
| Belian, B; Check, C; Manzor, O; Pawlak, J; Saravolatz, L | 1 |
| Jones, RN | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Longworth, DL | 1 |
| Fresnadillo Martínez, MJ; Garcia Sánchez, JE | 1 |
| Cartwright, FD; Kenny, GE | 1 |
| Appelbaum, PC; Davies, TA; Dewasse, BE; Jacobs, MR; Nagai, K | 1 |
| Frothingham, R | 2 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Alvirez-Freites, EJ; Carter, JL; Cynamon, MH | 1 |
| Gottlieb, T; Leroi, MJ; Siarakas, S | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Appelbaum, PC; Bozdogan, B; Browne, FA; Clark, C; Dewasse, BE; Jacobs, MR | 1 |
| López, M; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Bello, S; Torres, A | 1 |
| Citron, DM; Goldstein, EJ; Schooley, S; Stein, GE; Tyrrell, KL | 1 |
| López, M; Rodriguez Díaz, JC; Royo, G; Ruiz, M | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Bosso, JA; Enzweiler, KA; White, RL | 1 |
| Piddock, L; Ricci, V | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Kaatz, GW; Schooley, S; Stein, GE | 1 |
| Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA | 1 |
| Tipperman, R | 1 |
| Chiba, K; Hagiwara, T; Hashimoto, K; Sugiyama, A; Takahashi, S; Takasuna, K | 1 |
| Choo, CM; Lim, T; Lim, YS; Ngan, CC; Toh, GL | 1 |
| Hwang, DG | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Martinez, FJ | 1 |
| Brooks, TJ; Lever, MS; Sefton, AM; Simpson, AJ; Steward, J | 1 |
| Bernabo, J; Eiguchi, K; Farinati, A; Miller, RD; Molestina, RE; Ramirez, JA; Summersgill, JT; Uriarte, SM | 1 |
| Eick, S; Pfister, W; Sachse, S; Schmidt, KH; Schmitt, A | 1 |
| Mah, FS | 1 |
| Schooley, S; Stein, GE | 1 |
| Greisman, J; Hoban, CJ; Hoban, DJ; Noreddin, AM; Schurek, KN; Siemens, CG; Smith, HJ; Zhanel, GG | 1 |
| Ba, BB; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC | 1 |
| Herrygers, L; Lane, LC; Levine, JM; Nix, D; Noecker, RJ; Snyder, RW | 1 |
| García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Bitterman, A; Chruscicki, DA; Cohn, S; Donnenfeld, E; Perry, HD; Solomon, R | 1 |
| Hoepelman, I | 1 |
| Crawford, SA; Jorgensen, JH; McElmeel, LM; Whitney, CG | 1 |
| Herrygers, LA; Lane, LC; Levine, JM; Noecker, RJ | 1 |
| Brooks, TJ; Lever, MS; Nelson, M; Piercy, T; Simpson, AJ; Steward, J | 1 |
| Bloom, A; Donnenfeld, ED; Nedrud, C; Perry, HD; Snyder, RW; Solomon, R; Stein, J | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Berger, RE | 1 |
| Kim, DH; O'Brien, TP; Stark, WJ | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Anon, JB | 1 |
| Bower, KS; Burka, JM; Howard, RS; Kuzmowych, CP; Stutzman, RD; Vanroekel, RC | 1 |
| Durrie, DS; Trattler, W | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Kumar, R; Marx, DP; Moshirfar, M | 1 |
| Dick, JD; Kim, DH; O'Brien, TP; Stark, WJ | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Steward, J | 1 |
| Hickman, S; Hunold, AC; Kleinmann, G; Larson, S; LeBoyer, R; Mamalis, N; Neuhann, IM; Olson, RJ | 1 |
| Maclellan, D; Price, FW; Price, MO | 1 |
| Heinze, A; Holzgrabe, U | 1 |
| Bakri, SJ; Beer, PM; Costello, P; Falk, NS; Melendez, JA; Peters, GB; Singh, RJ | 1 |
| Cornish, W; Knowles, S; Phillips, EJ; Rachlis, A; Simor, AE; Tailor, SA | 1 |
| Aronowicz, JD; Caudle, D; McCulley, JP; Shine, WE | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J | 1 |
| Feiz, V; Kang, PC; Mirzaian, G; Moshirfar, M | 1 |
| Apple, DJ; Chew, J; Hunter, B; Kleinmann, G; Larson, S; Mamalis, N; Olson, RJ; Stevens, S | 2 |
| Paramasivan, NC; Somasundaram, S | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Black, JA; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Boom, WH; Charlebois, ED; Daley, CL; Debanne, SM; Dietze, R; Eisenach, KD; Hadad, DJ; Jankus, DD; Johnson, JL; Maciel, E; Palaci, M; Peloquin, CA | 1 |
| Cavanagh, HD; Ly, LT; Petroll, WM | 1 |
| Drlica, K; Malik, M | 1 |
| Fiscella, RG; Jensen, MK | 2 |
| Dhalla, IA; Juurlink, DN; Kopp, A; Mamdani, MM; Rochon, PA; Simor, AE | 1 |
| Asbell, PA; Bottone, EJ; Epstein, SP | 1 |
| Gordon, YJ; Kowalski, BR; Kowalski, RP; Mah, FS; Romanowski, EG; Thompson, PP | 1 |
| Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ | 1 |
| Drudy, D; Fanning, S; Kyne, L; O'Gaora, P; O'Mahony, R; Quinn, T | 1 |
| Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C | 1 |
| Bast, DJ; De Azavedo, JC; Downar, J; Duncan, CL; Kilburn, L; Kong, B; Lad, S; Low, DE | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Murthy, SI; Sahu, SK; Sangwan, VS; Thomas, R | 1 |
| Flynn, HW; Flynn, PM; Miller, D; Ozdek, SC | 1 |
| Hunter, B; Kleinmann, G; Larson, S; Mamalis, N; Olson, RJ; Stevens, S | 1 |
| Basavanthappa, S; Feiz, V; Moshirfar, M; Vitale, AT; Wegelin, JA; Wolsey, DH | 1 |
| Ong-Tone, L | 2 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| D'Azevedo, PA; Francisco, W; Oliveira, AD | 1 |
| Kubendiran, G; Mitchison, DA; Paramasivan, CN; Sulochana, S | 1 |
| Amyes, SG; Dobay, O; Ghidán, A; Matuz, M; Nagy, K; Rozgonyi, F | 1 |
| Catero, M | 1 |
| Gidoh, M | 1 |
| Flynn, HW; Harper, T; Miller, D | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| Bower, KS; Burka, JM; Kuzmowych, CR; Stutzman, RD; VanRoekel, RC | 1 |
| Blondeau, JM; Hedlin, P | 1 |
| Barequet, IS; Belkin, M; Habot-Wilner, Z; Lavinsky, F; Rosner, M; Ziv, H | 1 |
| da Costa, CF; de Almeida, MV; de Souza, MV; Lourenço, MC; Saraiva, MF; Vicente, FR | 1 |
| Fiscella, RG; Jensen, MK; Lewis, CC | 1 |
| Mamalis, N | 1 |
| Espandar, L; Meyer, JJ; Moshirfar, M | 1 |
| Hiddemen, JW; McCartney, MD; Rice, RL; Shepard, AR; Wax, MB; Williams, KK | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Amico, LM; Bucci, FA; Evans, RE | 1 |
| Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T | 1 |
| Allen, J; Coleman, DJ; Davies, GR; Fourie, B; Kanyok, T; Levin, J; Lienhardt, C; Mitchison, DA; Mthiyane, T; Reddy, C; Rustomjee, R; Sirgel, FA; Sturm, AW | 1 |
| Balzli, CL; Caballero, AR; Huang, B; McCormick, CC; O'Callaghan, RJ; Smith, E; Tang, A; Wigington, L | 1 |
| Bohigian, GM | 1 |
| Hatou, S; Yamada, M; Yoshida, J | 1 |
| Dunn, S; Holland, EJ; Kim, T; Lane, SS; Raizman, M | 1 |
| Hatou, S; Minagawa, Y; Yamada, M; Yoshida, J; Yoshida, T | 1 |
| Chew, J; Hunter, B; Jensen, M; Kleinmann, G; Mamalis, N; Meyer, JJ; Moshirfar, M; Stevens, S; Werner, L | 1 |
| Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N | 1 |
| Arias, CA; Cárdenas, AM; Castañeda, E; Díaz, L; Díaz, PL; Hidalgo, M; Reyes, J; Rincón, S; Vanegas, N | 1 |
| Fiscella, RG; Jensen, MK; Mooney, B; Moshirfar, M | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Berg, PD; Eid, I; Elbash, AR; Schrier, A; Smith, EF | 1 |
| Scoper, SV | 1 |
| Horstkotte, MA; Knobloch, JK; Mack, D; Rohde, H; Von Osten, H | 1 |
| Drlica, K; Gennaro, ML; Hussain, S; Malik, M; Shi, L | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Aihara, M; Eguchi, S; Minami, K; Miyanaga, M; Miyata, K; Sawaguchi, S; Shiroma, H | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Holland, EJ; Lane, SS; Lindstrom, RL | 1 |
| McCulley, JP | 1 |
| Alam, MR; Garg, P; Gopinathan, U; Krishnaiah, S; Reddy, AK; Sharma, S | 1 |
| Hori, Y; Inoue, T; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Sakamoto, M; Tano, Y; Yokokura, S | 1 |
| Callegan, MC; Moyer, AL; Novosad, BD; Ramadan, RT; Wiskur, B | 1 |
| Betanzos-Cabrera, G; Cancino-Díaz, JC; Cancino-Díaz, ME; González-González, G; Juárez-Verdayes, MA | 1 |
| de Almeida, CG; de Almeida, MV; Diniz, CG; Le Hyaric, M; Saraiva, MF; Silva, VL | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Blondeau, JM; Borsos, SD; Hesje, CK | 1 |
| Atkins, HS; Brew, SD; Brooks, TJ; Laws, TR; MacMillan, AP; Simpson, AJ; Spencer, S; Thirlwall, RE | 1 |
| Kobayakawa, S; Ooki, K; Tochikubo, T; Tsuji, A | 1 |
| Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A | 2 |
| Araújo, DP; de Almeida, MV; de Carvalho, GS; de Souza, MV; Saraiva, MF; Tran Huu Dau, ME | 1 |
| Donskey, CJ; Ellis-Reid, T; Gerding, DN; Jump, RL; Pultz, MJ; Riebel, W; Riggs, MM; Salata, RA; Sethi, AK | 1 |
| Agarwal, T; Chawla, B; Nayak, N; Satpathy, G; Shah, VM; Sharma, N; Tandon, R; Titiyal, JS; Vajpayee, RB | 1 |
| Banaszkiewicz, A; Młynarczyk, G; Obuch-Woszczatyński, P; Pituch, H; Radzikowski, A; Wultańska, D | 1 |
| Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Anwar, Z; Mostafa, H; Radi, AE; Wahdan, T | 1 |
| Chen, XY; Doi, N; Duan, HF; Fu, Y; Li, Q; Ma, Y | 1 |
| Lee, HB; Park, HY; Shin, JH | 1 |
| Davis, LT; Fiscella, RG; Glickman, RD; Kumar, N; Nijm, LM; Peterson, RJ; Tu, EY; Ulanski, LJ | 1 |
| Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N | 1 |
| Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Proksch, JW; Ward, KW | 1 |
| Akova, YA; Babaoğlu, MÖ; Bozkurt, A; Çetinkaya, A; Çolak, M; Güngör, SG; Yasar, Ü | 1 |
| Hiratsuka, Y; Kobayakawa, S; Murakami, A; Tochikubo, T; Watabe, Y | 1 |
| Sano, C; Sato, K; Shimizu, T; Tatano, Y; Tomioka, H; Yamabe, S | 1 |
| Haas, W; Hesje, CK; Morris, TW; Pillar, CM; Sanfilippo, CM | 1 |
| Kim, SJ; Toma, HS | 1 |
| Bellini, LP; Bulla, MC; Martins, GM | 1 |
| Acharya, NR; Cevallos, V; Fintelmann, RE; Gaynor, BD; Hoskins, EN; Keenan, JD; Lietman, TM | 1 |
| Comstock, TL; Donnenfeld, ED; Proksch, JW | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Dave, SB; Kim, SJ; Toma, HS | 2 |
| Alekperov, SI; Boĭko, ÉV; Fokina, DV; Reĭtuzov, VA | 1 |
| Bertino, JS; Jones, RN; Segreti, J | 1 |
| Anand, RS; Doble, M; Paramasivan, CN; Somasundaram, S | 1 |
| Menchini, U; Mencucci, R; Paladini, I; Pellegrini-Giampietro, DE; Scartabelli, T | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Fukuda, M; Hori, Y; Inatomi, T; Kinoshita, S; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Ohashi, Y; Satake, Y; Shimazaki, J; Shimomura, Y; Uno, T; Yamada, M | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Bukatina, AA; Galkina, KY; Isaeva, YD; Makarova, MV; Moroz, AM; Nosova, EY | 1 |
| Fernandes, M; Mittal, V | 1 |
| Ben Eliahu, S; Bronshtein, R; Kleinmann, G; Lipnitzki, I; Marcovich, AL | 1 |
| Brown, H; Callegan, MC; Kamae, K; McEntire, MW; Mifflin, MD; Olson, RJ; Pettey, DH; Pettey, JH | 1 |
| Chung, JL; Kim, BY; Lee, JH; Lim, EH; Mah, FS; Seo, KY; Song, SW | 1 |
| Ohashi, Y; Suzuki, T | 1 |
| Bukatina, A; Isaeva, Y; Krylova, L; Makarova, M; Moroz, A; Nosova, E | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Balasubramanian, R; Banurekha, VV; Baskaran, D; Chandrasekar, C; Charles, N; Ganapathy, S; Gangadevi, NP; Iliayas, AS; Jagannath, K; Jawahar, MS; Kumar, MM; Kumar, SR; Kumar, V; Mohan, V; Narayanan, PR; Paramasivan, CN; Parthasarathy, RT; Ponnuraja, C; Rahman, F; Ramachandran, R; Raman, B; Sakthivel, MR; Selvakumar, N; Shanmugam, G; Venkatesan, P | 1 |
| Helmy, SA | 1 |
| Kalavathy, CM; Kaliamurthy, J; Nelson Jesudasan, CA; Parmar, P; Thomas, PA | 1 |
| Lu, J; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y | 1 |
| Ghaly, H; Jörns, A; Rustenbeck, I | 1 |
| Mizrahi, V; Warner, DF | 1 |
| Geffen, N; Mimouni, M; Rosen, E; Segev, F | 1 |
| Fukuda, M; Sasaki, H | 1 |
| Mifflin, MD; Olson, RJ; Pettey, JH | 1 |
| Ai, J; Jin, J; Liu, Q; Ruan, Q; Shao, L; Sun, F; Yu, S; Zhang, B; Zhang, W | 1 |
| Chung, WK; Kim, KH; Kim, MJ; Lee, JH; Lee, S; Park, JH; Tchah, H; Yoon, Y | 1 |
| Corelli, F; Frosini, M; Saponara, S; Sgaragli, G | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Carrijo-Carvalho, LC; Carvalho, FR; de Freitas, D; E Silva, FB; Teixeira, A | 1 |
| Chiang, CY; Rieder, HL; Van Deun, A | 1 |
| Li, C; Li, YR; Liu, JC; Piao, HR; Wei, ZY; Zhang, W; Zheng, CJ | 1 |
| Dong, L; Fu, Y; Huang, H; Huo, F; Jing, W; Li, Y; Ma, Y; Pang, Y; Zhao, L; Zong, Z | 1 |
| Baiza-Durán, L; Casillas-Magallanes, M; Gómez-Bastar, PA; González-Lomelí, M; Lizárraga-Corona, A; Mercado-Sesma, AR; Montoya-Sánchez, IM; Mora-González, A; Ochoa-Tabares, JC; Olvera-Montaño, O; Oregon-Miranda, AA; Orozco-Carroll, M; Páez-Garza, JH; Pérez-Balbuena, AL; Sandoval-Delgadillo, LI; Saucedo-Rodríguez, LR; Villanueva-Najera, MA | 1 |
| Alffenaar, JWC; Kosterink, JGW; Pranger, AD; van der Werf, TS | 1 |
| Abdel-Meguid, AAE; Elmenofy, TMI; Gabr, AF; Nassef, MAEH; Said, MM | 1 |
| Capparelli, E; Catanzaro, DG; Rodwell, TC; Seifert, M | 1 |
| Aung, KJM; Decroo, T; Kuaban, C; Noeske, J; Piubello, A; Rieder, HL; Van Deun, A | 1 |
| Fujimoto, K; Goto, K; Hashimoto, K; Iguchi, T; Kishino, H; Mori, K; Suzuki, T; Watanabe, K | 1 |
| Affolabi, D; de Jong, BC; Decroo, T; Dusabe, T; Habimana, YM; Migambi, P; Mulders, W; Ngabonziza, JCS; Niyigena, EB; Rigouts, L; Supply, P; Ushizimpumu, B; Van Deun, A | 1 |
| Ding, H; Wan, L; Wu, Y; Yang, W; Zhang, B; Zhang, W | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
| Wan, L; Wu, Y; Zhang, W; Zhang, Y | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| He, Y; Li, X | 1 |
| Agrawal, D; Chatterjee, S; Gangwe, AB; Gomase, SN; Mishra, M; Parchand, SM | 1 |
| Ding, Y; Jiang, M; Wan, X; Xie, F; Zhang, J | 1 |
19 review(s) available for moxifloxacin and gatifloxacin
| Article | Year |
|---|---|
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Rifamycins; Tuberculosis | 2009 |
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Fluoroquinolone-isatin hybrids and their biological activities.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Moxifloxacin; Oxazolidinones; Patient Selection; Quinolines; Treatment Outcome; United States; United States Food and Drug Administration; Virginiamycin | 2001 |
Microbial drug resistance and the roles of the new antibiotics.
Topics: Acetamides; Anti-Infective Agents; Atovaquone; Aza Compounds; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Moxifloxacin; Naphthoquinones; Oxazolidinones; Proguanil; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae; Vancomycin; Vancomycin Resistance; Virginiamycin | 2001 |
Pharmacologic considerations for cataract surgery.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Quinolines; Triamcinolone Acetonide; Vancomycin | 2004 |
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2004 |
Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections.
Topics: Administration, Topical; Aza Compounds; Bacterial Infections; Eye Infections; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Quinolines | 2004 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pneumonia; Quinolines; Respiratory Tract Infections | 2004 |
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Meta-Analysis as Topic; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae | 2005 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Evidence-Based Medicine; Family Practice; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; United States; United States Food and Drug Administration | 2007 |
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2008 |
Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Bacteria; Bacterial Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Quinolines | 2012 |
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Randomized Controlled Trials as Topic; Treatment Outcome; Tuberculosis | 2016 |
Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
Topics: Antitubercular Agents; Bacterial Proteins; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Mycobacterium tuberculosis; Prospective Studies; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2016 |
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary | 2019 |
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network Meta-Analysis; Tuberculosis; Tuberculosis, Pulmonary | 2022 |
31 trial(s) available for moxifloxacin and gatifloxacin
| Article | Year |
|---|---|
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis, Pulmonary | 2008 |
A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability.
Topics: Adult; Anterior Chamber; Aza Compounds; Conjunctiva; Eye; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperemia; Irritants; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Pain; Pupil; Quinolines | 2004 |
Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.
Topics: Aged; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines | 2005 |
Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery.
Topics: Administration, Topical; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Cataract Extraction; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines | 2005 |
The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy.
Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Astigmatism; Aza Compounds; Double-Blind Method; Epithelium, Corneal; Female; Fluorophotometry; Fluoroquinolones; Gatifloxacin; Humans; Lasers, Excimer; Male; Middle Aged; Moxifloxacin; Myopia; Photorefractive Keratectomy; Prospective Studies; Quinolines; Wound Healing | 2005 |
A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK.
Topics: Adult; Antibiotic Prophylaxis; Aza Compounds; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Humans; Keratectomy, Subepithelial, Laser-Assisted; Keratomileusis, Laser In Situ; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines; Treatment Outcome; Wound Healing | 2005 |
The effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Child; Epithelium, Corneal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Male; Middle Aged; Moxifloxacin; Postoperative Care; Postoperative Complications; Prospective Studies; Quinolines; Wound Healing | 2005 |
Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
Topics: Administration, Topical; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Perioperative Care; Prospective Studies; Quinolines; Staphylococcus epidermidis | 2005 |
Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Epithelium, Corneal; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microscopy, Confocal; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines | 2005 |
Vitreous penetration of topical moxifloxacin and gatifloxacin in humans.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Biological Availability; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Lens, Crystalline; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Pseudophakia; Quinolines; Retinal Diseases; Vitrectomy; Vitreous Body; Vitreous Hemorrhage | 2006 |
Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Biological Availability; Chromatography, High Pressure Liquid; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Lens Implantation, Intraocular; Male; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Prospective Studies; Quinolines | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Single-Blind Method; Tuberculosis, Pulmonary | 2006 |
Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Gatifloxacin; Humans; Instillation, Drug; Lens Implantation, Intraocular; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Preoperative Care; Prospective Studies; Quinolines | 2007 |
The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy.
Topics: Anti-Infective Agents; Aza Compounds; Corneal Opacity; Double-Blind Method; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Lasers, Excimer; Moxifloxacin; Photorefractive Keratectomy; Postoperative Care; Postoperative Period; Quinolines; Refraction, Ocular; Time Factors; Treatment Outcome; Visual Acuity; Wound Healing | 2007 |
Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Antitubercular Agents; Aqueous Humor; Aza Compounds; Conjunctiva; Dose-Response Relationship, Drug; Eye Infections, Bacterial; Eyelids; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Surgical Wound Infection; Treatment Outcome | 2008 |
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Nonlinear Dynamics; Ofloxacin; Pyrazinamide; Quinolines; Rifampin; Sputum | 2008 |
Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Chromatography, High Pressure Liquid; Cornea; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution; Wound Healing | 2008 |
Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Drug Delivery Systems; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines; Tissue Distribution | 2008 |
A comparison of fluoroquinolone penetration into human conjunctival tissue.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefazolin; Child; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Tobramycin; Treatment Outcome; Visual Acuity; Young Adult | 2010 |
Comparison of the effects of fourth-generation fluoroquinolones on epithelial healing after photorefractive keratectomy.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Aza Compounds; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Photorefractive Keratectomy; Postoperative Care; Quinolines; Surgical Wound Infection; Time Factors; Visual Acuity; Wound Healing; Young Adult | 2010 |
Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery.
Topics: Aged; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Cataract; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Endophthalmitis; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Preoperative Care; Prospective Studies; Quinolines; Surgical Wound Infection; Treatment Outcome | 2011 |
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Levofloxacin; Middle Aged; Moxifloxacin; Nasopharynx; Ofloxacin; Prospective Studies; Quinolines; Staphylococcal Infections | 2011 |
Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Azepines; Biological Availability; Chromatography, Liquid; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Quinolines; Tandem Mass Spectrometry | 2011 |
Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Intravitreal Injections; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Staphylococcus epidermidis; Young Adult | 2011 |
Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cornea; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2012 |
Changes in ocular flora in eyes exposed to ophthalmic antibiotics.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Longitudinal Studies; Moxifloxacin; Ofloxacin; Quinolines | 2013 |
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Recurrence; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2013 |
The effect of gatifloxacin 0.3% or moxifloxacin 0.5% on corneal healing, ocular tolerability and toxicity following pterygium surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Benzalkonium Compounds; Double-Blind Method; Epithelium, Corneal; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Preservatives, Pharmaceutical; Pterygium | 2016 |
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Conjunctivitis, Bacterial; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Oxazines; Staphylococcus; Young Adult | 2018 |
Comparative Study Between Topical Gatifloxacin 0.5% and Moxifloxacin 0.5% as a Prophylactic Measure Before Intraocular Surgery.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Corynebacterium diphtheriae; Eye Infections, Bacterial; Female; Gatifloxacin; Humans; Intraocular Pressure; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Staphylococcus aureus | 2019 |
249 other study(ies) available for moxifloxacin and gatifloxacin
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
Topics: Animals; Antimalarials; Antiparasitic Agents; Cell Line; Drug Design; Fibroblasts; Fluoroquinolones; Humans; Inhibitory Concentration 50; Plasmodium; Quantitative Structure-Activity Relationship; Toxoplasma | 2004 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
Topics: Anti-Bacterial Agents; Azo Compounds; Cell Line; Escherichia coli; Humans; Hydrocarbons, Aromatic; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Staphylococcus aureus; Sulfhydryl Compounds | 2006 |
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial | 2007 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2007 |
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Topics: Animals; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Japan; Levofloxacin; Liver; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolines; Spleen | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae | 2008 |
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Mice; Mice, Inbred BALB C; Nocardia; Nocardia Infections; Oxazolidinones; Treatment Outcome | 2008 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia | 2008 |
Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Animals; Disease Models, Animal; Esters; Female; Fluoroquinolones; Humans; Molecular Structure; Organophosphonates; Osteomyelitis; Prodrugs; Rats | 2008 |
Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Amines; Animals; Cell Line; Diphosphonates; Female; Fluoroquinolones; Molecular Structure; Osteomyelitis; Prodrugs; Rats; Structure-Activity Relationship | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Topics: Aza Compounds; Clostridioides difficile; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
Topics: Aminoquinolines; Antimalarials; Ciprofloxacin; Ferrous Compounds; Metallocenes; Plasmodium falciparum; Prodrugs | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Topics: Aminopyridines; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium avium Complex; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Quinolines; Rifampin; Species Specificity | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis | 2010 |
Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
Topics: Anti-Infective Agents; Chloramphenicol; Escherichia coli; Fluoroquinolones; Levofloxacin; Ofloxacin; Oxazines; Structure-Activity Relationship | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Cell Line; Cell Survival; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fluoroquinolones; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcus; Stereoisomerism; Structure-Activity Relationship | 2011 |
Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; DNA Cleavage; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium leprae; Mycobacterium tuberculosis; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2013 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
Topics: Anti-Bacterial Agents; Cell Survival; Drug Resistance, Multiple, Bacterial; Escherichia coli; HeLa Cells; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Quinolines; Rhodanine; Structure-Activity Relationship | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
Topics: Anti-Infective Agents; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrophotometry, Infrared; Thiazolidines | 2014 |
Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
Topics: Anti-Infective Agents; Candida albicans; Candidiasis; Escherichia coli; Escherichia coli Infections; Humans; Rhodanine; Staphylococcal Infections; Staphylococcus aureus; Thiones; Triazoles | 2015 |
Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Drug Resistance, Multiple, Bacterial; Furans; Gram-Negative Bacteria; Gram-Positive Cocci; Ibuprofen; Indomethacin; Mice; Pyrazoles | 2015 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Cell Line; Cell Proliferation; Chalcone; Dose-Response Relationship, Drug; Guanidines; Humans; Hydrazones; Microbial Sensitivity Tests; Molecular Structure; Salmonella typhimurium; Structure-Activity Relationship | 2016 |
Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
Topics: Anti-Bacterial Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Pseudomonas aeruginosa; Salmonella typhimurium; Staphylococcus aureus; Structure-Activity Relationship; Triazines | 2018 |
Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Acetyltransferases; Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Escherichia coli Proteins; Fatty Acid Synthase, Type II; Guanidines; Humans; Indoles; Microbial Sensitivity Tests; Molecular Docking Simulation; Protein Conformation; Semicarbazides; Structure-Activity Relationship | 2019 |
Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
Topics: Anti-Bacterial Agents; Binding Sites; Cell Line; Cell Survival; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrazoles; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Triazines | 2019 |
Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rhodanine; Structure-Activity Relationship; Tryptophan | 2019 |
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship | 2019 |
Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
Topics: Animals; Antitubercular Agents; Cell Survival; Chlorocebus aethiops; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Isatin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles; Vero Cells | 2019 |
Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bees; Candida albicans; Cell Membrane; Cornea; Eye Infections, Bacterial; Female; Humans; Keratitis; Lysine; Melitten; Mice, Inbred C57BL; Microbial Sensitivity Tests; Proof of Concept Study; Rabbits; Unilamellar Liposomes | 2020 |
Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
Topics: | 2020 |
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus | 2022 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Gatifloxacin and moxifloxacin: two new fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gastrointestinal Diseases; Gatifloxacin; Humans; Moxifloxacin; Pneumonia; Quinolines; Staphylococcus aureus | 2000 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Klebsiella; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Urinary Tract Infections | 2000 |
Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cation Transport Proteins; DNA-Binding Proteins; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Gatifloxacin; Long QT Syndrome; Mice; Models, Animal; Moxifloxacin; Patch-Clamp Techniques; Piperazines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quinolines; Rabbits; Trans-Activators; Tumor Cells, Cultured | 2001 |
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Quinolines; Streptococcus pneumoniae | 2001 |
Conventional dogma applied to quinolones? Time for a change.
Topics: 4-Quinolones; Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Outcome Assessment, Health Care; Pneumococcal Infections; Quinolines; Respiratory Tract Diseases; Streptococcus pneumoniae | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
[Novel antibiotics active against Gram-positive bacteria].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; Moxifloxacin; Peptides; Quinolines | 2000 |
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities
Topics: 4-Quinolones; Acetamides; Aminoglycosides; Anti-Bacterial Agents; Aza Compounds; Erythromycin; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Ketolides; Linezolid; Macrolides; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mycoplasma hominis; Mycoplasma pneumoniae; Oxazolidinones; Quinolines; Tetracyclines; Tigecycline; Ureaplasma urealyticum; Virginiamycin | 2001 |
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Quinolines; Selection, Genetic; Serotyping; Streptococcus pneumoniae | 2001 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Combinations; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nasal Cavity; Quinolines; Tuberculosis | 2002 |
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Topics: Acetamides; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Fluoroquinolones; Fusidic Acid; Gatifloxacin; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Quinolines; Sensitivity and Specificity; Vancomycin | 2002 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Selection, Genetic; Streptococcus pneumoniae | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Multivariate Analysis; Mutation; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Pneumonia, Pneumococcal; Quinolines; Recurrence; Risk Factors; Streptococcus pneumoniae | 2003 |
Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Community-Acquired Infections; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Respiratory Tract Infections | 2003 |
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Oxazolidinones; Quinolines; Spain | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
Topics: Administration, Oral; Anti-Bacterial Agents; Aza Compounds; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Formularies, Hospital as Topic; Gatifloxacin; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high?
Topics: Adult; Aza Compounds; Blood Bactericidal Activity; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Serum Bactericidal Test; Staphylococcus | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Topics: Administration, Oral; Animals; Aza Compounds; Blood Pressure; Chloralose; Disease Models, Animal; Dogs; Electrocardiography; Female; Fluoroquinolones; Gatifloxacin; Halothane; Heart Block; Heart Rate; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Rabbits; Risk Assessment; Time Factors; Torsades de Pointes; Ventricular Function, Left | 2004 |
Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma hominis; Quinolines; Sampling Studies; Sensitivity and Specificity; Singapore; Tetracycline | 2004 |
Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
Topics: Adult; Aza Compounds; Child; Conjunctivitis, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Pregnancy; Quinolines | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Topics: Animals; Anthrax; Anti-Infective Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Survival Analysis | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytes; Pneumonia, Bacterial; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
In vitro antibacterial activity of fluoroquinolones against Porphyromonas gingivalis strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteroidaceae Infections; DNA Gyrase; DNA Primers; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Periodontitis; Porphyromonas gingivalis; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2004 |
Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae | 2004 |
Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching.
Topics: Anti-Infective Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Levofloxacin; Moxifloxacin; Ofloxacin; Quality Control; Quinolines; Reference Standards; Reproducibility of Results | 2004 |
Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Chromatography, High Pressure Liquid; Cornea; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2004 |
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors | 2004 |
Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2004 |
Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols.
Topics: Animals; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Microscopy, Electron, Scanning; Moxifloxacin; No-Observed-Adverse-Effect Level; Quinolines; Rabbits | 2005 |
Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Dexamethasone; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Glucocorticoids; Melioidosis; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines | 2005 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Aza Compounds; Cell Line; Cell Movement; Chemokine CCL2; Chlamydia Infections; Chlamydophila pneumoniae; Endothelium, Vascular; Fluoroquinolones; Gatifloxacin; Humans; Interleukin-8; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytosis; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Dexamethasone; Disease Models, Animal; Female; Fluoroquinolones; Francisella tularensis; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Survival Analysis; Tularemia | 2005 |
Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields.
Topics: Animals; Aqueous Humor; Aza Compounds; Chromatography, High Pressure Liquid; Collagen; Cornea; Diffusion; Drug Carriers; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Male; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method.
Topics: Acetamides; Anti-Bacterial Agents; Automation; Aza Compounds; Fluoroquinolones; Gatifloxacin; Linezolid; Moxifloxacin; Oxazolidinones; Protein Binding; Quinolines; Reproducibility of Results; Serum Albumin, Bovine; Technology, Pharmaceutical; Ultrafiltration | 2006 |
Glucose homeostasis abnormalities and gatifloxacin.
Topics: Aza Compounds; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Tularemia | 2006 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratomileusis, Laser In Situ; Keratoplasty, Penetrating; Lasers, Excimer; Microbial Sensitivity Tests; Moxifloxacin; Myopia; Photorefractive Keratectomy; Postoperative Complications; Pseudomonas Infections; Quinolines; Staphylococcal Infections | 2006 |
Hydrophilic acrylic intraocular lens as a drug-delivery system: Pilot study.
Topics: Acrylic Resins; Animals; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Drug Delivery Systems; Fluoroquinolones; Gatifloxacin; Lens Implantation, Intraocular; Lenses, Intraocular; Male; Moxifloxacin; Pilot Projects; Quinolines; Rabbits | 2006 |
Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Enterococcus; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pyrrolidines; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2006 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea.
Topics: Animals; Aza Compounds; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Immunohistochemistry; Membrane Proteins; Microscopy, Confocal; Moxifloxacin; Ophthalmic Solutions; Phosphoproteins; Quinolines; Rabbits; Zonula Occludens-1 Protein | 2006 |
Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
Topics: Antitubercular Agents; Aza Compounds; Chloramphenicol; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Protein Synthesis Inhibitors; Quinolines | 2006 |
Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery.
Topics: Ambulatory Surgical Procedures; Anti-Bacterial Agents; Aza Compounds; Drug Costs; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmologic Surgical Procedures; Postoperative Complications; Quinolines | 2006 |
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Topics: Aged; Aged, 80 and over; Aza Compounds; Case-Control Studies; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Time Factors | 2006 |
Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Cataract Extraction; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Postoperative Complications; Quinolines; Retrospective Studies | 2006 |
Hydrophilic acrylic intraocular lens as a drug-delivery system for fourth-generation fluoroquinolones.
Topics: Acrylic Resins; Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Biological Availability; Drug Delivery Systems; Female; Fluoroquinolones; Gatifloxacin; Lens Implantation, Intraocular; Lens, Crystalline; Lenses, Intraocular; Moxifloxacin; Quinolines; Rabbits | 2006 |
High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Dipeptides; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Enterotoxins; Enzyme Inhibitors; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Reserpine; Ribotyping; Sequence Analysis, DNA; Verapamil | 2006 |
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Quinolines; Selection, Genetic; Streptococcus pneumoniae; Topoisomerase II Inhibitors | 2006 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Anti-Bacterial Agents; Aza Compounds; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Moxifloxacin; Postoperative Complications; Quinolines; Wound Healing | 2006 |
Evaluation of the penetration of fluoroquinolones in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2006 |
In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
Topics: Anti-Infective Agents; Aza Compounds; Candida; Colony Count, Microbial; Eye Infections, Fungal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Moxifloxacin; Quinolines; Retrospective Studies | 2006 |
Collagen shields as a drug delivery system for the fourth-generation fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Biological Dressings; Chromatography, High Pressure Liquid; Collagen; Drug Delivery Systems; Fluoroquinolones; Gatifloxacin; Male; Moxifloxacin; Quinolines; Rabbits | 2007 |
Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Postoperative Complications; Quinolines; Retrospective Studies; Vitreous Body | 2007 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Brazil; Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2007 |
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Time Factors | 2006 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Hungary; Microbial Sensitivity Tests; Moxifloxacin; Mutation, Missense; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2006 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Topics: Acetamides; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Biological Availability; Coagulase; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Microbiological Techniques; Moxifloxacin; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus; Vancomycin; Virginiamycin | 2007 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Topics: Anti-Infective Agents; Antimutagenic Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Osmolar Concentration; Quinolines | 2007 |
Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Corneal Diseases; Disease Models, Animal; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Male; Moxifloxacin; Quinolines; Rabbits; Wound Healing | 2007 |
Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives.
Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Lipids; Molecular Structure; Moxifloxacin; Quinolines; Streptococcus pneumoniae; Structure-Activity Relationship | 2007 |
Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations.
Topics: Anti-Infective Agents; Aza Compounds; Drug Prescriptions; Fluoroquinolones; Gatifloxacin; Humans; Medicaid; Medicare; Moxifloxacin; Ophthalmic Solutions; Practice Patterns, Physicians'; Quinolines; Retrospective Studies; United States; Utilization Review | 2007 |
The increasing problem of antibiotic resistance.
Topics: Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines | 2007 |
Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Topics: Adult; Amikacin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratomileusis, Laser In Situ; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines | 2007 |
Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%.
Topics: Animals; Aza Compounds; Collagen Type IV; Cornea; Disease Models, Animal; Drug Evaluation, Preclinical; Epithelium; Fluoroquinolones; Gatifloxacin; Gene Expression Profiling; Immunohistochemistry; Lasers, Excimer; Moxifloxacin; Ophthalmic Solutions; Photorefractive Keratectomy; Quinolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Wound Healing | 2007 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluoroquinolones; Gatifloxacin; Immunologic Factors; Keratitis; Levofloxacin; Lipopolysaccharides; Macrophages, Peritoneal; Male; Methicillin Resistance; Mice; Mice, Inbred C3H; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2008 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratomileusis, Laser In Situ; Methicillin Resistance; Moxifloxacin; Postoperative Complications; Quinolines; Rabbits; Specific Pathogen-Free Organisms; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2008 |
Endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Postoperative Complications; Quinolines; Vitreous Body | 2008 |
In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Child; Conjunctiva; Drug Resistance, Microbial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2008 |
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Topics: Aza Compounds; Conjunctiva; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Staphylococcus epidermidis | 2008 |
Comparison of the effects of fourth-generation fluoroquinolones on corneal re-epithelialization in rabbit eyes.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Corneal Diseases; Disease Models, Animal; Epithelium, Corneal; Ethanol; Female; Fluoroquinolones; Gatifloxacin; Image Processing, Computer-Assisted; Male; Moxifloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Prospective Studies; Quinolines; Rabbits; Wound Healing | 2008 |
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity | 2008 |
[Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colombia; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Enterococcus; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2008 |
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Cross-Sectional Studies; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines; Retrospective Studies | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
Antimicrobial activity of acrylic intraocular lenses soaked in fourth generation fluoroquinolones.
Topics: Acrylic Resins; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Drug Delivery Systems; Fluoroquinolones; Gatifloxacin; In Vitro Techniques; Lenses, Intraocular; Moxifloxacin; Quinolines; Staphylococcus aureus | 2008 |
Biofilm formation is not necessary for development of quinolone-resistant "persister" cells in an attached Staphylococcus epidermidis population.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Prosthesis-Related Infections; Quinolines; Quinolones; Staphylococcal Infections; Staphylococcus epidermidis | 2008 |
In vitro model of mycobacterial growth arrest using nitric oxide with limited air.
Topics: Air; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Mycobacterium; Nitric Oxide Donors; Quinolines; Rifampin; Triazenes | 2009 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Retrospective Studies; Staphylococcus; Streptococcus | 2010 |
Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Preoperative Care; Quinolines | 2009 |
Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Keratitis; Moxifloxacin; Ophthalmic Solutions; Postoperative Complications; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Time Factors | 2009 |
Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis.
Topics: Anti-Infective Agents; Aza Compounds; Conjunctivitis; Corneal Ulcer; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcus epidermidis | 2009 |
Antibacterial activity of lipophilic fluoroquinolone derivatives.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Fluoroquinolones; Gatifloxacin; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2009 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2009 |
Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Brucella melitensis; Brucellosis; Colony Count, Microbial; Doxycycline; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Spleen; Treatment Outcome | 2009 |
Aqueous humor penetration of fourth-generation fluoroquinolone ophthalmic solutions given by multiple administration in a rabbit model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Cataract Extraction; Drug Administration Schedule; Eye; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Models, Animal; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Surgical Wound Infection | 2009 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome | 2009 |
Synthesis and antitubercular evaluation of new fluoroquinolone derivatives coupled with carbohydrates.
Topics: Antitubercular Agents; Aza Compounds; Carbohydrates; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Quinolines | 2010 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Specific Pathogen-Free Organisms; Staphylococcal Infections; Treatment Outcome | 2010 |
Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA.
Topics: Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; Feces; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Hospitals; Humans; Moxifloxacin; Ohio; Quinolines | 2010 |
[Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age].
Topics: Aza Compounds; Ciprofloxacin; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Female; Fluoroquinolones; Gastrointestinal Tract; Gatifloxacin; Genotype; Humans; Infant; Infant, Newborn; Male; Metronidazole; Moxifloxacin; Phenotype; Quinolines; Species Specificity; Vancomycin | 2010 |
Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Ophthalmic Solutions; Penicillin Resistance; Pneumococcal Infections; Quinolines; Rabbits; Severity of Illness Index; Streptococcus pneumoniae; Time Factors | 2010 |
Electrochemical determination of gatifloxacin, moxifloxacin and sparfloxacin fluoroquinolonic antibiotics on glassy carbon electrode in pharmaceutical formulations.
Topics: Anti-Infective Agents; Aza Compounds; Carbon; Electrochemistry; Electrodes; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Moxifloxacin; Quinolines; Tablets | 2010 |
[Susceptibility test of the Mycobacterium avium complex to sixteen anti-infective agents].
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Quinolines | 2010 |
An adaptable HPLC method for the analysis of frequently used antibiotics in ocular samples.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Chromatography, High Pressure Liquid; Contact Lenses, Hydrophilic; Eye; Fluoroquinolones; Gatifloxacin; Linear Models; Linezolid; Moxifloxacin; Oxazolidinones; Quinolines; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Vitreous Body | 2010 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2010 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Disease Susceptibility; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Sequence Analysis, DNA | 2011 |
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Conjunctivitis, Bacterial; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus Infections; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Streptococcal Infections | 2010 |
Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aza Compounds; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Gentamicins; Microscopy, Electron, Scanning; Models, Animal; Moxifloxacin; Quinolines; Rabbits | 2010 |
Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Quinolines | 2011 |
In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.
Topics: Anti-Bacterial Agents; Aza Compounds; Azepines; Bacteria; Benzalkonium Compounds; Drug Interactions; Fluoroquinolones; Gatifloxacin; Microbial Viability; Moxifloxacin; Quinolines; Time Factors | 2011 |
Preventing endophthalmitis after cataract surgeries.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Quinolines | 2011 |
Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Risk Factors; Staphylococcal Infections; Staphylococcus aureus | 2011 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
[The effectiveness of intraocular delivery of 5-fluoroquinolones for prophylaxis of intraocular infection].
Topics: Anti-Bacterial Agents; Aza Compounds; Eye Infections, Bacterial; Eye Injuries; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Levofloxacin; Male; Military Medicine; Moxifloxacin; Ofloxacin; Quinolines; Warfare | 2011 |
Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Aza Compounds; Base Sequence; Binding Sites; Crystallography, X-Ray; DNA Gyrase; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Humans; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Protein Conformation; Quinolines | 2011 |
In vitro comparison of the cytotoxic effects of clinically available ophthalmic solutions of fluoroquinolones on human keratocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Corneal Keratocytes; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; L-Lactate Dehydrogenase; Microscopy, Phase-Contrast; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2011 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Russia; Tuberculosis, Pulmonary | 2013 |
Cotrimoxazole-resistant Nocardia sclerokeratitis: effective therapy with fourth-generation fluoroquinolones.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Nocardia; Nocardia Infections; Quinolines; Scleritis; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
Hydrophilic acrylic intraocular lens as a drug delivery system: influence of the presoaking time and comparison to intracameral injection.
Topics: Acrylic Resins; Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Chromatography, High Pressure Liquid; Drug Delivery Systems; Female; Fluoroquinolones; Gatifloxacin; Hydrophobic and Hydrophilic Interactions; Injections, Intraocular; Lens Implantation, Intraocular; Lenses, Intraocular; Male; Moxifloxacin; Prednisolone; Quinolines; Rabbits; Time Factors; Tissue Distribution | 2013 |
The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Equipment Contamination; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Injections, Intraocular; Moxifloxacin; Needles; Quinolines; Time Factors | 2013 |
Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Biological Availability; Chromatography, High Pressure Liquid; Conjunctiva; Cornea; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Tissue Distribution; Vitreous Body | 2013 |
Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefmenoxime; Corneal Ulcer; Drug Combinations; Drug Synergism; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas; Quinolines; Staphylococcus; Streptococcus; Tobramycin | 2013 |
Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.
Topics: Antitubercular Agents; Automation, Laboratory; Aza Compounds; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Topics: Acetamides; Adult; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Limit of Detection; Linezolid; Male; Moxifloxacin; Norfloxacin; Oxazolidinones; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tinidazole; Young Adult | 2013 |
Spectrum of bacterial keratitis at a tertiary eye care centre in India.
Topics: Aza Compounds; Ciprofloxacin; Corneal Ulcer; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus | 2013 |
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence | 2014 |
Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Flavin-Adenine Dinucleotide; Fluoroquinolones; Gatifloxacin; Glucose; Insulin-Secreting Cells; Mice; Mice, Knockout; Microscopy, Electron, Transmission; Mitochondria; Moxifloxacin; NADP; Quinolines; Sulfonylurea Receptors | 2014 |
Shortening treatment for tuberculosis--to basics.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Pulmonary | 2014 |
Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing.
Topics: Animals; Anti-Bacterial Agents; Cell Proliferation; Cell Survival; Corneal Injuries; Disease Models, Animal; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Rabbits; Time Factors; Wound Healing | 2015 |
Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Bacteria; Cadaver; Conjunctiva; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Moxifloxacin; Needles; Povidone-Iodine | 2015 |
In vivo 3D measurement of moxifloxacin and gatifloxacin distributions in the mouse cornea using multiphoton microscopy.
Topics: Animals; Anti-Bacterial Agents; Cornea; Fluoroquinolones; Gatifloxacin; Imaging, Three-Dimensional; Intravital Microscopy; Mice; Microscopy, Fluorescence; Moxifloxacin | 2016 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Toxicity of Intracameral Injection of Fourth-Generation Fluoroquinolones on the Corneal Endothelium.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Azepines; Cell Survival; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Human Umbilical Vein Endothelial Cells; Humans; Injections, Intraocular; Male; Moxifloxacin; Ophthalmic Solutions; Rabbits; Topoisomerase II Inhibitors | 2016 |
Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Bangladesh; Blood Glucose; Cameroon; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Niger; Pilot Projects; Prevalence; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Synthesis and Antimicrobial Evaluation of (Z)-5-((3-phenyl-1H-pyrazol-4- yl)methylene)-2-thioxothiazolidin-4-one Derivatives.
Topics: Anti-Bacterial Agents; Bacillus subtilis; Candida albicans; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Norfloxacin; Oxacillin; Pyrazoles; Stereoisomerism; Streptococcus mutans; Thiohydantoins | 2016 |
Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2017 |
Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single Nucleotide | 2019 |
Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; Cameroon; Child; Drug Administration Schedule; Female; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Niger; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Fluoroquinolones suppress gluconeogenesis by inhibiting fructose 1,6-bisphosphatase in primary monkey hepatocytes.
Topics: Animals; Anti-Bacterial Agents; Cells, Cultured; Fructose-Bisphosphatase; Gatifloxacin; Gluconeogenesis; Hepatocytes; Macaca fascicularis; Male; Moxifloxacin | 2020 |
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; High-Throughput Nucleotide Sequencing; Humans; Kanamycin; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Rwanda; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2020 |
Effects of moxifloxacin and gatifloxacin stress on growth, photosynthesis, antioxidant responses, and microcystin release in Microcystis aeruginosa.
Topics: Antioxidants; Chlorophyll; Chlorophyll A; Gatifloxacin; Microcystins; Microcystis; Moxifloxacin; Photosynthesis | 2021 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |
Toxicity, biodegradation of moxifloxacin and gatifloxacin on Chlamydomonas reinhardtii and their metabolic fate.
Topics: Biodegradation, Environmental; Chlamydomonas reinhardtii; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Photosynthesis | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
Topics: Anti-Bacterial Agents; Cefuroxime; Ciprofloxacin; Colistin; Eye Infections; Fluoroquinolones; Gatifloxacin; Humans; Longitudinal Studies; Moxifloxacin; Ofloxacin; Retrospective Studies | 2022 |
Conjunctival sac flora and drug susceptibility analysis in normal children in East China.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Conjunctiva; Female; Gatifloxacin; Humans; Lacrimal Apparatus; Male; Microbial Sensitivity Tests; Moxifloxacin; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus; Tobramycin | 2023 |